volrustomig: Clinical Trials

4 trials of volrustomig, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

2 active not recruiting, 2 recruiting. 4 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 34Active not recruiting 2, Recruiting 2

Follow volrustomig: new trials by email Literature Review of volrustomig trials Research Report on volrustomig

Trials (filtered) newest first · largest first

All 4 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Global Study of Volrustomig (MEDI5752) for Participants With Unresected Locally Advanced Head and Neck Squamous Cell Carcinoma Following Definitive Concurrent Chemoradiotherapy
volrustomig - Locally Advanced Head and Neck Squamous Cell Carcinoma
Phase 3RecruitingAstraZeneca11452023-12-142026-09-30
MEDI5752 in Combination With Carboplatin Plus Pemetrexed in Unresectable Pleural Mesothelioma
Volrustomig, Pemetrexed, Carboplatin - Unresectable Pleural Mesothelioma
Phase 3Active not recruitingAstraZeneca8632023-11-092026-10-23
A Global Study of Volrustomig (MEDI5752) Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy for Participants With Metastatic Non-small Cell Lung Cancer.
Volrustomig, Pembrolizumab, Carboplatin - Metastatic Non-small Cell Lung Cancer
Phase 3Active not recruitingAstraZeneca8952023-10-242026-10-09
Study of Volrustomig in Women With High Risk Locally Advanced Cervical Cancer (eVOLVE-Cervical)
Volrustomig, Placebo - Locally Advanced Cervical Cancer
Phase 3RecruitingAstraZeneca8002023-09-222026-11-10

Conditions studied

Carcinoma, Non-Small-Cell Lung (1)  ·  Mesothelioma (1)  ·  Mesothelioma, Malignant (1)

Sponsors

AstraZeneca (4)

Countries

Brazil (4)  ·  Canada (4)  ·  China (4)  ·  Germany (4)  ·  Italy (4)  ·  Japan (4)  ·  Poland (4)  ·  South Korea (4)  ·  Spain (4)  ·  Taiwan (4)  ·  Turkey (Türkiye) (4)  ·  United States (4)  ·  Belgium (3)  ·  France (3)  ·  India (3)

Top investigators

Arnaud Scherpereel, MD (1)  ·  Lisa Licitra, MD (1)  ·  Marjorie G Zauderer, MD (1)  ·  Robert Haddad, MD (1)

NIH funding

2023 (3)